Recently, the National Medical Products Administration announced that in accordance with the Implementation Regulations of the Drug Administration Law of the People's Republic of China and the Measures for the Administration of Drug Registration, the Administration has decided to cancel the registration certificates of 87 drugs, including Meglumine Pan Injection.
It is worth noting that out of the 87 drug registration certificates that were cancelled, 7 were "not re registered", while the rest were "cancelled upon application.". Many of the drugs that have been deregistered come from foreign-funded enterprises, including Pfizer, Novartis, Novo Nordisk, Sanofi, Bayer, and others. For example, multiple approvals from Novo Nordisk, such as insulin aspartate and insulin detecate, have been cancelled.
On April 21st, Novo Nordisk told the Daily Economic News that several products with cancelled drug approvals have been converted to production at Novo Nordisk's Tianjin production plant in China. Therefore, in accordance with national laws and regulations, the batch numbers of imported large packaging and sub packaging have been cancelled.
Novo Nordisk stated that several products have received new batch numbers, and this change will not affect the safety, effectiveness, quality control, or supply of the products.